ARMR Sciences Inc., America's biodefense technology company, has completed a private placement financing with strategic and institutional investors, with Joseph Gunnar & Co., LLC acting as placement agent. The funding will support the company's advancement toward human trials for its fentanyl vaccine, which is designed to prevent fatal overdoses and address threats from substances such as fentanyl.
The vaccine is backed by the U.S. Department of War and represents a critical shift in national strategy from reacting to overdoses to preventing them at the source. According to the company, fentanyl is the number one killer of U.S. adults aged 18 to 45, making this vaccine a crucial countermeasure.
ARMR Sciences is pioneering the first long-acting, preventive immunotherapy to stop synthetic drug overdose before it begins. Through its foundational license, the company is backed by early-stage research funding from the U.S. Department of Defense. The private placement will support continued development and clinical progression of the vaccine.
Qualified prospective investors who meet the qualifications of an “accredited investor” can invest $5,000 in this offering and become a shareholder and owner of ARMR. For more information, visit https://armrsciences.com/.
The announcement was made available at https://ibn.fm/t39w2. This development underscores the growing focus on biodefense technologies to combat the synthetic drug crisis.
